Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.

被引：6
|
作者：
Tam, Constantine Si Lun
Roberts, Andrew Warwick
Anderson, Mary Ann
Dawson, Sarah-Jane
Hicks, Rodney J.
Burbury, Kate
Turner, Gillian
Di Iulio, Juliana
Bressel, Mathias
Westerman, David A.
Agarwal, Rishu
Pott, Christiane
Dreyling, Martin H.
Dawson, Mark A.
Seymour, John Francis
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.7520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7520
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
    Portell, Craig A.
    Wages, Nolan A.
    Kahl, Brad S.
    Budde, Lihua E.
    Chen, Robert W.
    Cohen, Jonathon B.
    Petroni, Gina
    Williams, Michael E.
    BLOOD, 2019, 134
  • [2] The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.
    Tam, Constantine Si Lun
    Roberts, Andrew Warwick
    Anderson, Mary Ann
    Dawson, Sarah-Jane
    Hicks, Rodney J.
    Pott, Christiane
    Westerman, David A.
    Burke, Glenda
    Kamel, Sarah
    Dreyling, Martin H.
    Dawson, Mark A.
    Seymour, John Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
    Handunnetti, Sasanka M.
    Anderson, Mary Ann
    Burbury, Kate
    Hicks, Rodney J.
    Birbirsa, Besiat
    Bressel, Mathias
    Di Iulio, Juliana
    Westerman, David Alan
    Lade, Stephen
    Agarwal, Rishu
    Dawson, Mark A.
    Dawson, Sarah-Jane
    Koldej, Rachel
    Ritchie, David
    Seymour, John F.
    Roberts, Andrew W.
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [4] A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma
    Kim, Myung Sun
    Banerjee, Titas
    Chen, Andy
    Danilov, Alexey
    MacKinnon, Renee
    Thurlow, Bria
    Thakurta, Sujata
    Orand, Kirsten
    Degnin, Catherine
    Park, Byung
    Spurgeon, Stephen E.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 722 - 724
  • [5] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Goto, Hideki
    Ito, Satoshi
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Zeng, Jiewei
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy A.
    Izutsu, Koji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
  • [6] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Izutsu, Koji
    Goto, Hideki
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Mukherjee, Nabanita
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy
    Ishizawa, Kenichi
    ANNALS OF ONCOLOGY, 2023, 34 : S1428 - S1428
  • [7] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Hideki Goto
    Satoshi Ito
    Masahiro Kizaki
    Masaki Yamaguchi
    Noriko Fukuhara
    Koji Kato
    Toko Saito
    Yasuhito Terui
    Sumiko Okubo
    Tomomi Soshin
    Jiewei Zeng
    Hideyuki Honda
    Mohamed Badawi
    Jeremy A. Ross
    Koji Izutsu
    International Journal of Clinical Oncology, 2024, 29 : 232 - 240
  • [8] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [9] A retrospective observational study of rapid titration of venetoclax (VEN) in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)
    Babalola, Tijesuni
    Ayers, Emily C.
    Douvas, Michael G.
    Foster, Laahn
    Densmore, John
    Williams, Michael E.
    Portell, Craig Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] IBRUTINIB PLUS WITH VENETOCLAX FOR THE TREATMENT OF PRIMARY REFRACTORY MANTLE-CELL LYMPHOMA: A REAL LIFE EXPERIENCE
    Fabbri, A.
    Cencini, E.
    Congiu, A. G.
    Miglino, M.
    Rigacci, L.
    Bocchia, M.
    HAEMATOLOGICA, 2019, 104 : 161 - 161
12345